Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Infection-related arthritis
How do you differentiate between chikungunya-induced arthritis and RA during sporadic outbreaks or in regions with higher prevalence?
Related Questions
How do you decide when it is appropriate to discontinue long-term antibiotic therapy in a patient with Whipple's disease?
Do you recommend chronic oral suppressive antibiotics after initial intensive treatment of 6-8 weeks in patients with culture-negative prosthetic joint or bone infections with retained hardware?
What strategies do you implement in your clinic to ensure comprehensive screening and timely diagnosis of syphilis in populations with risk factors for sexually transmitted infections?
Would you give long term antistreptococcal antibiotic prophylaxis to a patient who presents with features of poststreptococcal reactive arthritis but who also meets criteria for Acute Rheumatic Fever?
Do you routinely transition to PO antibiotics for patients with native joint septic arthritis whom have undergone washout and the organism is not S. aureus?
How do you focus your history and exam to better identify potential cases of chikungunya presenting with rheumatic symptomas in the setting of global travel?
How would you manage a patient with strongly suspected Lyme arthritis and negative bacterial synovial fluid cultures who was started on empiric antibiotics against typical bacterial pathogens arthritis before arthrocentesis and collection of cultures?
Do you provide empiric doxycycline for Lyme Disease to asymptomatic patients after a tick bite who haven't developed Erythema migrans or are not sure it was an Ixodes tick?
In cases of significant BMD loss without fractures while on long-term denosumab therapy and in the presence of very low bone turnover markers without secondary causes for bone loss, what is best approach: continuing denosumab anyway or switching to a bisphosphonate?
How would you approach the evaluation and management of isolated vasculitis with aneurysms involving the segmental hepatic arteries causing hepatic hemorrhage in an otherwise healthy patient in his 80s?
